Company Performance#

Inspire Medical Systems (INSP) delivered impressive results for the first quarter of 2026, reporting an adjusted earnings per share (EPS) of $0.10. This figure significantly exceeded the anticipated loss of $0.33, marking a positive surprise of 130.3%. Revenue also surpassed expectations, reaching $204.6 million, a 1.6% increase compared to the same period last year, largely due to enhanced market penetration.

Financial Highlights#

  • Revenue: $204.6 million, up 1.6% year-over-year
  • Adjusted EPS: $0.10, beating the forecasted loss of $0.33
  • Operating Cash Flow: $12.8 million, an improvement of $20 million from Q1 2025
  • Adjusted EBITDA Margin: 17.5%, an increase of 100 basis points

Despite these positive financial metrics, the company faced challenges related to coding and reimbursement, which they are actively working to resolve.

Market Reaction#

Following the earnings announcement, Inspire Medical's stock saw a modest increase of 0.51% in aftermarket trading, closing at $56.99. This slight rise indicates cautious optimism among investors, who are balancing the strong earnings report against the company's revised guidance and ongoing operational challenges.

Outlook & Guidance#

Inspire Medical has adjusted its full-year 2026 revenue guidance to a range of $825 million to $875 million, a decrease from earlier estimates. The company anticipates a revenue decline of 9%-11% in Q2 2026 due to uncertainties surrounding coding and reimbursement, as well as the impact of the WISeR program. However, they expect improvements in the latter half of the year.

Executive Commentary#

CEO Tim Herbert emphasized the company's ability to drive growth despite external challenges, stating, "Our Q1 results reflect our ability to drive growth through market penetration." CFO Rick Buchholz highlighted the company's strong cash position and lack of debt, which allows for investments in strategic initiatives aimed at improving operational efficiency.

Risks and Challenges#

Inspire Medical faces significant risks related to coding and reimbursement uncertainties, which could impact future revenue. The company is committed to addressing these challenges as part of their long-term growth strategy.